<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>obesity treatment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/obesity-treatment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Jan 2026 17:36:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>obesity treatment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Access Ensures Semaglutide’s Full Potential is Achieved</title>
		<link>https://bioengineer.org/access-ensures-semaglutides-full-potential-is-achieved/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 17:36:01 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Diabetes Management** **Kısa Açıklama:** 1. **Semaglutide Access:** Makalenin ana odağı]]></category>
		<category><![CDATA[Diabetes medication affordability** **Açıklama:** 1. **Semaglutide access barriers:** Makalenin ana teması ilacın potansiyeline ulaşmasının önündeki erişim engelleri (özellikle sigorta kapsam]]></category>
		<category><![CDATA[GLP-1 agonist benefits]]></category>
		<category><![CDATA[healthcare equity]]></category>
		<category><![CDATA[ilaca erişimin sağlanması. 2. **Insurance Coverage:**]]></category>
		<category><![CDATA[Insurance Coverage]]></category>
		<category><![CDATA[Insurance coverage reform]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **Semaglutide access barriers]]></category>
		<category><![CDATA[Makalenin içeriği ve ana temaları dikkate alınarak oluşturulmuş 5 uygun etiket: **Semaglutide Access]]></category>
		<category><![CDATA[obesity treatment]]></category>
		<category><![CDATA[Obesity treatment equity]]></category>
		<guid isPermaLink="false">https://bioengineer.org/access-ensures-semaglutides-full-potential-is-achieved/</guid>

					<description><![CDATA[The potential of semaglutide, a novel antidiabetic drug, to transform the management of obesity and diabetes is captured in the keen insights provided by Gasoyan and Rothberg. Their comprehensive analysis highlights that robust coverage of this medication is essential for users to fully realize its benefits. As the prevalence of obesity and associated metabolic disorders [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319933</post-id>	</item>
		<item>
		<title>Brain electrical stimulation suppresses appetite. A new frontier in obesity treatment?</title>
		<link>https://bioengineer.org/brain-electrical-stimulation-suppresses-appetite-a-new-frontier-in-obesity-treatment/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 12 Aug 2024 04:13:42 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[appetite suppression]]></category>
		<category><![CDATA[metabolic syndrome management]]></category>
		<category><![CDATA[Non-invasive Neuromodulation]]></category>
		<category><![CDATA[obesity treatment]]></category>
		<category><![CDATA[transcranial electrical stimulation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/brain-electrical-stimulation-suppresses-appetite-a-new-frontier-in-obesity-treatment/</guid>

					<description><![CDATA[The R&#038;D on neuromodulation technology for the treatment and management of metabolic syndrome conducted by a team led by Dr. Ki-young Shin of Human Care Electro-Medical Device Research Center, Electro-Medical Equipment Research Division of KERI is underway smoothly. The R&#038;D on neuromodulation technology for the treatment and management of metabolic syndrome conducted by a team [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">231341</post-id>	</item>
	</channel>
</rss>
